JP2011522795A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522795A5
JP2011522795A5 JP2011508582A JP2011508582A JP2011522795A5 JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5 JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
molecule
composition according
region
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522795A (ja
Filing date
Publication date
Priority claimed from US12/387,359 external-priority patent/US7915222B2/en
Application filed filed Critical
Publication of JP2011522795A publication Critical patent/JP2011522795A/ja
Publication of JP2011522795A5 publication Critical patent/JP2011522795A5/ja
Pending legal-status Critical Current

Links

JP2011508582A 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法 Pending JP2011522795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US61/050,336 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US12/387,359 2009-05-01
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (2)

Publication Number Publication Date
JP2011522795A JP2011522795A (ja) 2011-08-04
JP2011522795A5 true JP2011522795A5 (cg-RX-API-DMAC7.html) 2012-03-15

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508582A Pending JP2011522795A (ja) 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法

Country Status (25)

Country Link
US (3) US7915222B2 (cg-RX-API-DMAC7.html)
EP (2) EP2279206B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011522795A (cg-RX-API-DMAC7.html)
KR (1) KR20110014180A (cg-RX-API-DMAC7.html)
CN (1) CN102037010A (cg-RX-API-DMAC7.html)
AR (1) AR071672A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244448B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912249A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723698C (cg-RX-API-DMAC7.html)
CL (1) CL2009001082A1 (cg-RX-API-DMAC7.html)
DK (1) DK2279206T3 (cg-RX-API-DMAC7.html)
EA (1) EA201001749A1 (cg-RX-API-DMAC7.html)
ES (1) ES2539840T3 (cg-RX-API-DMAC7.html)
HK (1) HK1208230A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150552T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025256T2 (cg-RX-API-DMAC7.html)
IL (1) IL208691A (cg-RX-API-DMAC7.html)
MX (1) MX2010011503A (cg-RX-API-DMAC7.html)
NZ (1) NZ589020A (cg-RX-API-DMAC7.html)
PL (1) PL2279206T3 (cg-RX-API-DMAC7.html)
PT (1) PT2279206E (cg-RX-API-DMAC7.html)
SI (1) SI2279206T1 (cg-RX-API-DMAC7.html)
TW (2) TWI454278B (cg-RX-API-DMAC7.html)
WO (1) WO2009137424A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007914B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2660776T3 (es) * 2011-10-10 2018-03-26 Medimmune Limited Tratamiento para la artritis reumatoide
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
WO2014070840A2 (en) * 2012-10-30 2014-05-08 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
EA201692126A1 (ru) * 2014-04-25 2017-03-31 Бристол-Маерс Сквибб Компани Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
NZ262248A (en) * 1993-01-21 1998-09-24 Univ Georgia Vaccines comprising a compound having a lysergic ring coupled to an immunogenic protein and its use in treating fescue toxicosis
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK0892643T4 (da) 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
CZ303959B6 (cs) 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
PL377603A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
EP1670499A4 (en) 2003-08-04 2009-07-22 Bristol Myers Squibb Co METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
WO2007024964A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Similar Documents

Publication Publication Date Title
JP2011522795A5 (cg-RX-API-DMAC7.html)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
HRP20150552T1 (hr) Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2010529957A5 (cg-RX-API-DMAC7.html)
FI3415531T3 (fi) Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
JP2015531750A5 (cg-RX-API-DMAC7.html)
JP2019510739A5 (cg-RX-API-DMAC7.html)
JP2015508757A5 (cg-RX-API-DMAC7.html)
JP2017528419A5 (cg-RX-API-DMAC7.html)
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
NZ603623A (en) Tcr complex immunotherapeutics
JP2004248677A5 (cg-RX-API-DMAC7.html)
JP2012500020A5 (cg-RX-API-DMAC7.html)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2019507589A5 (cg-RX-API-DMAC7.html)
JP2014502955A5 (cg-RX-API-DMAC7.html)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
JP2011524420A5 (cg-RX-API-DMAC7.html)
JP2017500018A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
JP2016511277A5 (cg-RX-API-DMAC7.html)
FI3378535T3 (fi) Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita
JP2016502515A5 (cg-RX-API-DMAC7.html)
JP2015522252A5 (cg-RX-API-DMAC7.html)